| Literature DB >> 33658942 |
Yuqi Yang1, Zhuo-Xun Wu1, Jing-Quan Wang1, Qiu-Xu Teng1, Zi-Ning Lei1, Sabrina Lusvarghi2, Suresh V Ambudkar2, Zhe-Sheng Chen1, Dong-Hua Yang1.
Abstract
OTS964 is a potent T-LAK cell-originated protein kinase (TOPK) inhibitor. Herein, we investigated the interaction of OTS964 and multidrug resistance (MDR)-associated ATP-binding cassette sub-family G member 2 (ABCG2). The cell viability assay indicated that the effect of OTS964 is limited in cancer drug-resistant and transfected cells overexpressing ABCG2. We found that the known ABCG2 transporter inhibitor has the ability to sensitize ABCG2-overexpressing cells to OTS964. In mechanism-based studies, OTS964 shows inhibitory effect on the efflux function mediated by ABCG2, and in turn, affects the pharmacokinetic profile of other ABCG2 substrate-drugs. Furthermore, OTS964 upregulates ABCG2 protein expression, resulting in enhanced resistance to ABCG2 substrate-drugs. The ATPase assay demonstrated that OTS964 stimulates ATPase activity of ABCG2 in a concentration-dependent manner. The computational molecular docking analysis combined with results from ATPase assay suggested that OTS964 interacts with drug-binding pocket of ABCG2 and has substrate-like behaviors. Thus, OTS964 is an MDR-susceptible agent due to its interactions with ABCG2, and overexpression of ABCG2 transporter may attenuate its therapeutic effect in cancer cells.Entities:
Keywords: ABC transporter; ABCG2; OTS964; TOPK inhibitor; cancer
Year: 2021 PMID: 33658942 PMCID: PMC7917255 DOI: 10.3389/fphar.2021.620874
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810